Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
All News
A study of 90 consecutive male (50.3±11.1 years) with psoriatic arthritis (PsA) were were compared to 240 age matched controls without known cardiovascular (CV) diseases who underwent angiography for chest pain and/or multiple CV risk factors.
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
Similar to the findings in rheumatoid arthritis, lower levels of education can have predictable negative consequences. And the reasons for more heart attacks with lower educational levels is not entirely clear.
Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition.
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Disease Activity Pre-pregnancy During Pregnancy Post-pregnancy
Mild 10 6 4
Moderate 2 6 8
Severe 2 2 2
Colitis onset or worsening inflammatory bowel disease has been reported with either of the new IL-17 inhibitors, ixekizumab (IXE) and secukinumab (SEC). Large database studies show these to be rare.
Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Investigators analyzed a prospective study of patients with early axial spondyloarthritis (axSpA) to assess predictors of outcome.
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC.
Washington is always a great city to visit (even though there were a few protesters floating around the streets). I hope the posts I made were of interest to some readers. Here are my top 5 highlights from ACR 2016:
The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.
The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.
New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.
CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.
